Join the Ozanimod group to help and get support from people like you.
Ozanimod News
FDA Approves Bristol Myers Squibb’s Zeposia (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
PRINCETON, N.J.--(BUSINESS WIRE) May 27, 2021 – Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment...
FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of...
Further information
Related condition support groups
Ulcerative Colitis, Multiple Sclerosis